George Sands, Nisha Bansal and Wolfgang C. Winkelmayer/LinkedIn
Jun 5, 2026, 18:32
George Sands: A Thoughtful Editorial on Low-Dose Rivaroxaban in Advanced CKD
George Sands, Ex-Senior Medical Director of Pfizer, Principal of Sands Collaborative, shared a post on LinkedIn about a recent article by Nisha Bansal and Wolfgang C. Winkelmayer, published in JAMA, adding:
“Sharing a very thoughtful editorial by Bansal and Winkelmyer about a trial in CKD patients, stage 4 and 5.
This randomized study is very helpful. This patient population is very challenging to randomize in clinical trials.
This was a placebo-controlled trial vs low-dose rivaroxaban.
The editorial sums it all up beautifully; approximately 5-minute read.”
Title: Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
Authors: Nisha Bansal, Wolfgang C. Winkelmayer
Stay updated on all sceintific advances with Hemostasis Today.
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?